Enzalutamide Resistance | List of Frontiers open access articles

Original Research

Published on 09 Jun 2025

ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer

in Cancer Cell Biology

Jinpeng Cen
Jiading Guo
Xianzi Zeng
Xianlu Song
Shengdong Ge
Mingkun Chen
Qianyi Li
Yuzhong Yu
Daojun Lv
Shanchao Zhao

Frontiers in Cell and Developmental Biology

doi 10.3389/fcell.2025.1598400

3,598 views
1 citation

Review

Published on 25 Nov 2024

Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer

in Pharmacology of Anti-Cancer Drugs

Zhe Zhu
Wenjing Xuan
Chaohui Wang
Chancan Li

Frontiers in Oncology

doi 10.3389/fonc.2024.1481777

3,178 views
1 citation

Original Research

Published on 10 Mar 2021

Systematic Evaluation for the Influences of the SOX17/Notch Receptor Family Members on Reversing Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells

in Cancer Molecular Targets and Therapeutics

Zhongbo Du
Luo Li
Wei Sun
Pingyu Zhu
Shulin Cheng
Xuesong Yang
Chunli Luo
Xiaodong Yu
Xiaohou Wu

Frontiers in Oncology

doi 10.3389/fonc.2021.607291

4,697 views
13 citations

Mini Review

Published on 24 May 2018

Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer

in Cancer Molecular Targets and Therapeutics

Alexandra Vander Ark
Jingchen Cao
Xiaohong Li

Frontiers in Oncology

doi 10.3389/fonc.2018.00180

16,873 views
48 citations

Correction

Published on 25 Jun 2025

Correction: ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer

in Cancer Cell Biology

Jinpeng Cen
Jiading Guo
Xianzi Zeng
Xianlu Song
Shengdong Ge
Mingkun Chen
Qianyi Li
Yuzhong Yu
Daojun Lv
Shanchao Zhao

Frontiers in Cell and Developmental Biology

doi 10.3389/fcell.2025.1646699

1,570 views

Review

Published on 12 Jan 2026

Coactivator networks orchestrating noncanonical AR programs in enzalutamide-resistant CRPC

in Molecular and Cellular Oncology

Ephraim J. Gardner
Sasikumar Ponnusamy
Remi Adelaiye-Ogala

Frontiers in Oncology

doi 10.3389/fonc.2025.1748527

1,125 views

Original Research

Published on 15 Nov 2021

The circRAB3IP Mediated by eIF4A3 and LEF1 Contributes to Enzalutamide Resistance in Prostate Cancer by Targeting miR-133a-3p/miR-133b/SGK1 Pathway

in Molecular and Cellular Oncology

Dong Chen
Yaqin Wang
Feiya Yang
Adili Keranmu
Qingxin Zhao
Liyuan Wu
Sujun Han
Nianzeng Xing

Frontiers in Oncology

doi 10.3389/fonc.2021.752573

4,370 views
11 citations

Original Research

Published on 25 Apr 2022

Novel MDM2 Inhibitor XR-2 Exerts Potent Anti-Tumor Efficacy and Overcomes Enzalutamide Resistance in Prostate Cancer

in Pharmacology of Anti-Cancer Drugs

Meng Wu
Jingyi Cui
Huimin Hou
Ying Li
Shengjie Liu
Li Wan
Lili Zhang
Wei Huang
Gaoyuan Sun
Jingchao Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2022.871259

5,805 views
6 citations

Original Research

Published on 09 May 2023

A synthetic lethal screen for Snail-induced enzalutamide resistance identifies JAK/STAT signaling as a therapeutic vulnerability in prostate cancer

in Molecular Diagnostics and Therapeutics

Kathryn E. Ware
Beatrice C. Thomas
Pelumi D. Olawuni
Maya U. Sheth
Nathan Hawkey
M. Yeshwanth
Brian C. Miller
Katherine J. Vietor
Mohit Kumar Jolly
So Young Kim

Frontiers in Molecular Biosciences

doi 10.3389/fmolb.2023.1104505

6,053 views
10 citations

Articles

ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer

Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer

Systematic Evaluation for the Influences of the SOX17/Notch Receptor Family Members on Reversing Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells

Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer

Correction: ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer

Coactivator networks orchestrating noncanonical AR programs in enzalutamide-resistant CRPC

The circRAB3IP Mediated by eIF4A3 and LEF1 Contributes to Enzalutamide Resistance in Prostate Cancer by Targeting miR-133a-3p/miR-133b/SGK1 Pathway

Novel MDM2 Inhibitor XR-2 Exerts Potent Anti-Tumor Efficacy and Overcomes Enzalutamide Resistance in Prostate Cancer

A synthetic lethal screen for Snail-induced enzalutamide resistance identifies JAK/STAT signaling as a therapeutic vulnerability in prostate cancer